Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
SABCS 2025 – pumitamig replicates breast cancer findings
Global phase 2 data in TNBC look similar to earlier results in China.
Summit joins the global colorectal fight
The pivotal Harmoni-GI3 study has started enrolling patients.
Pfizer speeds ahead with bispecific development
The company will imminently start its third pivotal trial of PF-08634404.
Gastrointestinal is next for pumitamig
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
Moderna takes on IO Biotech
The group is expanding its mRNA-4359 trial to include first-line melanoma.
In triple-negative pumitamig concedes PD-L1-high disease
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
World Lung 2025 – pumitamig confirms its small-cell promise
Global data are in the same ballpark as Chinese results presented earlier this year.
